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Background: Breast cancer patients with positive estrogen receptor (ER) have a better prognosis. However, no
prognostic miRNA signature was reported in the ER-positive breast cancer. The aim of the study was to identify
and assess the prognostic significance of a miRNA signature in ER-positive breast cancer.
Methods: Two cohorts from The Cancer Genome Atlas (TCGA) dataset were used as training (n =596) and testing
set (n =319). Differential expression profiling was identified in the training set. And the prognostic value of the
miRNA signature was then assessed in the two cohorts.
Results: A total of 14 miRNAs were observed to be associated with the status of ER by significance analysis of
microarrays (SAM) in the training set. Patients were characterized as high score or low score group according to
the calculated risk scores from each miRNA. And patients in high score group had worse overall survival compared
with those in low score group both in the training and testing set.
Conclusions: Our study revealed a miRNA signature including 14 miRNAs associated with ER status which could act as
a prognostic marker in ER-positive breast cancer.
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Breast cancer is a heterogeneous disease that comprises
a range of subgroups with diverse clinical behaviors and
responses to treatment [1]. Many breast-cancer-related
genes have been investigated to explore the molecular
mechanism of carcinogenesis and diverse clinical outcome
of the disease [2-6]. Among them, some specific genes such
as estrogen receptor (ER) [7], progesterone receptor (PR)
[8] and human epidermal growth factor receptor 2 (HER2)
[9] have been used to identify different subgroups and indi-
cate different prognostic results with different treatment
modalities in the clinical. Patients with ER-positive status
which account for almost 70% of breast cancer always had
a better prognosis compared with those ER-negative types
[10]. However, ER-positive patients also have distinct
outcomes and almost 20% might relapse within 10 years
after surgery [11]. Thus, there is an urgent need to identify* Correspondence: zhuwei1983213@163.com; liu-ping@csco.org.cn
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unless otherwise stated.biomarkers that could predict prognostic outcome in pa-
tients with ER-positive breast cancer.
MicroRNAs (miRNAs) are short (approximately 22
nucleotides), single-stranded and highly conserved non-
coding RNAs which could regulate almost one-third
human genome based on either mRNA degradation or
translational repression through base pairing with the 3′-
untranslated region of target mRNAs at post-transcriptional
level [12,13]. Reportedly, miRNAs play important roles
in various biological processes, such as cellular develop-
ment, differentiation, proliferation, angiogenesis and me-
tabolism [14-17]. The prognostic value of miRNAs has
been explored in several cancer types, such as colon
cancer [18], nasopharyngeal carcinoma [19], hepatocellular
carcinoma [20] and glioma [21]. To date, no prognostic
miRNA signature for ER-positive breast cancer has been
reported. In the present study, we used data retrieved from
The Cancer Genome Atlas (TCGA, http://cancergenome.
nih.gov/) and identify a miRNA signature associated with
the status of ER which could act as a prognostic predicator
for ER-positive patients.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Expression profiles
The miRNA expression microarray data (Level 3) and cor-
responding clinical data for breast cancer patients were
obtained from The Cancer Genome Atlas (TCGA) database
(http://cancergenome.nih.gov) and Ref [22,23]. The data
from two independent platforms were classified into two
cohorts. The cohort with 596 patients (456 ER-positive and
140 ER-negative) undergone IlluminaHiSeq_miRNASeq
platform and the smaller dataset with 319 cases (251 ER-
positive and 68 ER-negative) from IlluminaGA_miRNASeq
platform were used as training and validation set, respect-
ively. As the data were obtained from TCGA, further ap-
proval by an ethics committee was not required.
Statistical analysis
The differential expression profile between ER-positive and
ER-negative cases in training set was assessed by using
significance analysis of microarrays (SAM) on BRB array
tools package which was developed by Richard Simon
and the BRB-ArrayTools Development Team [24]. And
P value <0.001 with fold change (FC) > 2.8 (log2 FC >1.5)
was considered significant. Risk score analysis was per-
formed to evaluate the association of ER associated miRNA
signature and overall survival of ER-positive patients. ROC
curves were used to identify the optimal cutoff value for
each miRNA to discriminate ER-positive from negative
cases. The score for each miRNA, denoted as S, was set
as 1 if the expression level was greater than the cutoffFigure 1 Different expression of 14 miRNAs associated with ER status
positive ER.value, otherwise was set as 0 [25]. A risk score formula
for predicting survival was developed based on a linear
combination of the expression level multiplied regression
coefficient derived from the univariate logistic regression




Sij  Bj . In the equation above,
Sij is the risk score for miRNA j on patient i, and Bj is the
weight of the risk score of miRNA j. Patients in the train-
ing and test set were divided into high score and low score
group according to the risk score. Overall survival curves
for the two groups were estimated by the Kaplan-Meier
methodology and compared using log-rank test.
Survival analyses were performed using SPSS version
16.0 for Windows (Statistical Package for Social Sciences,
Chicago, IL). All p values were two-sided and statistical
significance was defined as p < 0.05.Results
Identification of ER associated miRNA signature
A total of 14 miRNAs were identified to be associated with
ER status in the training set. Among them, 12 miRNAs
(miR-135b, miR-187, miR-18a, miR-210, miR-224, miR-
3200, miR-452, miR-455, miR-505, miR-584, miR-9-1 and
miR-9-2) were significantly up-regulated while two down-
regulated (miR-190b, miR-375) in ER-negative cases com-
pared with ER-positive patients (Figure 1A). As shown in
Figure 1B, each of the 14 miRNAs was significantlyin both training set (A) and validation set (B). N: negative ER; P:
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ing to the status of ER in the validation set.Prognostic value of ER associated miRNA signature in
ER-positive patients
By combining cases from the two cohorts, better overall
survival could be found (Figure 2) in the ER-positive pa-
tients compared with ER-negative cases (P = 0.019). To
assess the prognostic value of ER associated miRNA sig-
nature, 456 ER-positive cases in training set was divided
into high and low score group according to the median
risk score (ROC curves for each miRNA were present in
the Additional file 1: Figure S1). As shown in Figure 3A,
the up-regulated miRNAs identified in ER-negative cases
exhibit high expression in high score group and the down-
regulated miRNAs have high expression in low score group.
And the patients with high score tended to have poor over-
all survival. Kaplan-Meier curves for the two groups were
shown in Figure 3B. ER-positive patients in high score
group suffered worse overall survival than those in low
score group (P = 0.022).
In the testing set, similar expression distribution of the
miRNAs was found when the cutoff value for each miRNA,
the same regression coefficient and cutoff value of risk
score derived from the cases in the training phase was
applied. And high score group is also prone to exhibiting a
worse prognosis (Figure 3C). As shown in Figure 3D,Figure 2 Overall survival of breast cancer in the combined cohorts acprognosis of cases with high score was significantly worse
than those with low score (P = 0.018).
Discussion
Breast cancer is the most common malignancy and the
second leading cause of cancer death among women world-
wide [26]. Due to the distinct clinical, pathological and mo-
lecular features of the disease, the treatment, response to
therapy and corresponding clinical outcome varies greatly
[3]. With the help of molecular profiling and the identifica-
tion of intrinsic subtypes by specific genes, breast can-
cer patients could benefit from appropriate treatment
[27]. ER status is one of the strong factors in predicting
patients’ response to endocrine therapy and its determin-
ation has become a standard practice in the management
of breast cancer [28]. The level of ER was positively corre-
lated with the sensitivity of the endocrine therapy and
could predict tamoxifen resistance in breast cancer [29].
However, ER-positive patients are less chemosensitive
than ER-negative cases [30] so that adjuvant chemotherapy
might not be beneficial to some ER-positive breast tumors
[11]. And ER-positive patients also have distinct behaviors
and outcome due to different molecular features. Thus, a
biomarker which could accurately predict clinical outcome
in ER-positive patients with breast cancer is needed
urgently.
In the present study, we used miRNA expression micro-
array data from TCGA and divided the data into twocording to the status of ER.
Figure 3 Risk scores for the ER-associated miRNA signature and outcome in breast cancer patients with positive ER status. (A) Training
set and (C) validation set: (Top) survival status and duration of cases; (Middle) risk scores of miRNA signature; (Bottom) low and high score group
for the 14 miRNAs; Kaplan-Meier curves for the low score and high score groups in both training set (B) and validation set (D). Patients with high
score had worse overall survival than those with low score.
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forms. Following the strategy of using the larger cohort as
training set, and the smaller one as the validation set [31],
we identified 14 miRNAs which were significantly associ-
ated with the status of ER both in training and validation
set. The optimal cutoff value for each miRNA to discrim-
inate different status of ER was determined by ROC curve.The risk score calculated from expression of each
miRNA weighted by regression coefficient B fitted with
status of ER might reflect the tendency from positive to
negative status of ER. High score might be more likely re-
lated to negative status while low score to positive status.
To assess the prognostic value of the miRNA signature,
the ER-positive cases were divided into high and low score
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regulated in ER-negative breast cancer patients exhibited
high expression in high score group and two declined
miRNAs showed high expression level in low score
group. And the ER-positive patients in high score group
suffered poorer survival compared with low score group
both in the training stage and validation set.
Lowery et al. [32] found that a 6-miRNA signature could
predict status of ER, of which only miR-135b was consist-
ently included in the 14-miRNA signature in our study.
To some extent, difference of target population and/or the
entry criteria might be responsible for the phenomenon.
However, it was also reported that elevated miR-18a [33],
miR-505 [34], miR-9 and reduced miR-375 [35] were cor-
related to oestrogen receptor negativity. The results were
consistent with our findings. In addition, re-expression of
miR-375 could reverse tamoxifen resistance and epithelial-
mesenchymal transition-like properties in the established
tamoxifen-resistant breast cancer cells [36]. Moreover, high
expression of miR-187 in breast cancer could lead to a
more aggressive, invasive phenotype and may act as an
independent predictor of outcome [37]. Prognostic value
of miR-210 has been explored in many cancer types. Breast
cancer patients with elevated miR-210 might have a poor
outcome [38,39]. Huang et al. [40] found that miR-224
might act as an oncogene by directly suppressing the
RKIP tumor suppressor resulting in promoting metastasis
of breast cancer. A higher expression of miR-9 is associated
with lymph node metastasis [41] and could act as a pre-
dictor for local recurrence of breast cancer [35]. However,
the other 5 miRNAs were not explored so widely in breast
cancer and further researches are required to investi-
gate their complex molecular mechanisms.
The specificity of biomarkers based on a single miRNA
is generally poor [25]. Thus, we developed a risk score of
combination the 14 miRNAs associated with ER status and
multiplied their corresponding weight to survival and
found that the score could predict overall survival in
ER-positive patients. Better insights into the mechanism of
the 14-miRNA signature in breast cancer might contribute
to an understanding of the genetic aberrations that are
involved in tumor genesis, progression and response to
treatment.
In conclusion, the ER associated miRNA signature iden-
tified in our study might support a potential predictor to
indicate clinical outcome for ER-positive patients and
serve as potential molecular targets for new therapeutic
strategies, subsequently leading to improved outcomes.Additional file
Additional file 1: Figure S1. ROC curve analyses of 14 miRNAs for
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